Intellia's Lonvo-z Shows 91% Reduction in Severe HAE Attacks, Published in NEJM
NTLA sits 54% above its 52-week low of $7.95.
Summary
Intellia Therapeutics reported additional highly positive Phase 3 results for its gene-editing therapy, lonvo-z, in hereditary angioedema (HAE). The data, presented at a major congress and published in the New England Journal of Medicine, showed a 91% reduction in moderate/severe HAE attacks and an 89% reduction in attacks requiring on-demand treatment. This follows the initial announcement of positive topline Phase 3 results in late April, which led to a $194.6 million public offering. These comprehensive additional results, including strong efficacy across key secondary endpoints and publication in a top medical journal, significantly strengthen the drug's profile and potential for regulatory approval. A rolling Biologics License Application (BLA) submission for lonvo-z was initiated with the FDA in April.
At the time of this announcement, NTLA was trading at $12.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $7.95 to $28.25. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.